US health panel reviews J&J vaccine pause over rare clots
With the U.S. pause of Johnson & Johnson’s COVID-19 vaccine stretched into a second week, authorities are weighing whether to resume the shots the way European regulators decided to—with warnings of a “very rare” risk.